Breaking Down the Complexities of Non-Clear Cell RCC Entities

Monday, 18 November 2024 | Urogenital

In recent years, the field of kidney cancer has seen significant advancements, especially regarding treatment options for rarer subtypes beyond the more common clear cell renal cell carcinoma (ccRCC). Dr. Victor Grünwald, a medical oncologist specialising in genitourinary cancers at the University Hospital in Essen, Germany, shares insights into these emerging therapies, focusing on non-clear cell RCC (nccRCC), such as papillary RCC (pRCC), and other subentities. He also highlights the importance of the ESMO guidelines, which provide critical recommendations for treating rare RCC subtypes, while also emphasizing the increasing evidence supporting the effectiveness of combination therapies.

Viktor Grünwald

University Hospital Essen, Germany

This article was written by PEAK Medicals. All rights reserved.

Explore More

OncoNews

OncoNews

Lung Icon

Lung Cancer

Uterus Icon

Women's Cancers

Bladder Icon

Urogenital

GI Icon

Gastro-intestinal

Hematology Icon

Hematology

Other Solid Tumor Icon

Other Tumors

Related Posts

To continue, please login or sign up first